Telehealth is a legitimate route to care. That is worth saying first, because much of what gets written about online GLP-1 prescribing is written in a warning tone, and plenty of people get good care this way; it reaches people a clinic does not, in places a clinic is not, on schedules a clinic cannot offer. The problem with the sector is not that it exists but that its marketing is easier to read than its substance. Two services can present identically on a landing page and differ completely in whether a clinician with a license and a history is anywhere in the loop.
So this page takes the only approach that works without naming anyone: describe what a genuine prescribing relationship involves, and turn each part of it into a question a person can put to a service before signing up. A service that answers these questions plainly has said a lot. A service that cannot answer them has also said a lot.
A practical note on asking: questions asked before signing up get better answers than questions asked after, and written questions get better answers than spoken ones, because they can be answered at leisure and kept. A short message listing three of these questions is a reasonable thing to send any service, and the manner of the reply, prompt or evasive, plain or glossy, is itself part of the answer. None of this needs to be adversarial. The register that works is the ordinary one: this is a medical relationship, and medical relationships begin with a history and end with a plan, and a person is entitled to know what they are joining.
The prescriber, and the week six problem
The first two questions are structural. Who is the prescriber, and are they licensed in my state? Prescribing is state-licensed, and a reader is entitled to the name and credentials of the clinician actually writing the prescription, not just the name of the company on the invoice. The answer should be specific and unbothered; vagueness here is the oldest signal there is.
The second question matters more than the first: will I speak to them, and can I reach them afterwards? A questionnaire alone is a thinner interaction than a conversation, and it is worth being clear-eyed about that difference rather than alarmed by it. The decisive part is what happens after the prescription exists. Side effects arrive after the prescription, not before it, and the question that reveals a service's shape is the practical one: what happens in week six, when something is wrong at ten at night? A service with a real answer to that, a named clinician, a message route, a coverage arrangement, is offering a relationship. A service whose answer is a FAQ page is offering a transaction.
It also helps to know what the follow-up question is for. GLP-1 treatment is a months-long process in which doses step up on a schedule, side effects cluster around those steps, and the right conversation at the right week changes what happens next. A prescriber who sees a patient at week one and never again knows less each week that passes. That is not a telehealth problem specifically; plenty of in-person care has the same gap. It is simply the reason the reachability question belongs near the top of the list, above anything about apps, portals or onboarding.
The history a careful prescriber takes
The labels themselves define what a serious intake looks like, because the labels carry the contraindications a prescriber is supposed to apply. The class is contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, a point the site unpacks at The Boxed Warning on Your GLP-1 Label, Explained. Careful prescribers also ask about pancreatitis, gallbladder disease, pregnancy plans, covered at GLP-1s and Pregnancy Planning: What the Labels Say, and everything else on the medication list.
The question to put to a service is therefore simply: what do you ask about? A prescriber who never asks about thyroid cancer in the family is not being efficient; they are not in a position to apply the label's own contraindications. Those are the questions a careful prescriber asks, and their absence is informative in a way no advertisement can undo. Intake length is not the point; a short intake that hits the right subjects beats a long one that skips them.
GLP 1 Tracker AppWhatever prescribes and whatever fills, the daily record stays yours: doses, side effects and weight logged on your phone, with no account and nothing sent to anyone.
Get the app
What is actually being prescribed
The third question sounds simple and is not: what am I being prescribed? Branded product, an authorized generic, and a compounded preparation are three different things. They differ in what is in the box, in how the dose is expressed, and in which rules govern who made it. A reader who knows which of the three is arriving is in a position to ask the right follow-up questions; a reader who does not know is guessing about their own medicine.
If the answer is a compounded preparation, two pages on this site pick up exactly there: Questions to Ask Before Filling at a Compounding Pharmacy covers the pharmacy side, and Tracking Compounded Semaglutide: Extra Care, Extra Notes covers why the same dose can mean different things at different concentrations, and what that asks of a log. The adjacent question belongs in the same conversation: which pharmacy fills the prescription, and can I use my own? A service confident in its pharmacy answers that easily.
Subscriptions, records and data
Many telehealth services bundle the consultation, the prescriber relationship and the medicine into one subscription, which is convenient and also blurs lines worth seeing clearly. The questions to ask are: what does the subscription include, and what happens if I stop? Stopping should not have to mean guessing whether one loses the prescriber, the medicine, or the records, and the answer is knowable in advance. It is also worth knowing whether the record of the prescribing relationship, the history, the notes, the plan, can be taken with you to a local clinician, because continuity is the thing a bundled service is quietly holding.
The last question is about data. Health information entered into a service is held by that service, under its terms, on its schedule. Who sees the data, what is retained, what is shared, and what deletion looks like are fair questions with written answers. This site has its own position on that subject, laid out at Why Your GLP-1 Data Should Stay on Your Phone, offered here as a link rather than a pitch: the point is not that a tracking app and a prescribing service are the same thing, it is that data questions deserve answers in both cases, before rather than after.
Used together, these questions do something a review cannot: they let any reader evaluate any service, including services that did not exist when this page was written. The good answers are not exotic. A named prescriber, a real history, a reachable clinician, a plain statement of what is prescribed, a pharmacy one can name, an honest account of what stopping means, and a straight answer about data. Any service offering all seven is offering care. The reader's job is only to ask.
Frequently asked questions
Is telehealth a safe way to get a GLP-1 prescription?
Telehealth is a legitimate route to care, and plenty of people get good care this way; it also reaches people a clinic does not. No article can tell a reader whether a specific service is legitimate, so the useful move is comparing any service against what a genuine prescribing relationship involves: a named, licensed prescriber, a real medical history, a conversation rather than a form, and an answer to who you reach when something goes wrong. Those are answerable questions, and a service that answers them plainly has said a lot.
What questions should I ask a GLP-1 telehealth service before signing up?
Seven cover the ground. Who is the prescriber, and are they licensed in my state? Will I speak to them, and how do I reach someone afterwards? What medical history do they take? What am I actually being prescribed: branded product, generic, or a compounded preparation? Which pharmacy fills it, and can I use my own? What does the subscription include, and what happens if I stop? And who sees the data I enter? Each question has a reason behind it, and the reasons are the article.
Should a GLP-1 telehealth prescriber ask about my family history?
Yes, and the labels explain why. The class carries a contraindication for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and careful prescribers also ask about pancreatitis, gallbladder disease, pregnancy plans and the rest of the medication list. A prescriber who never asks those questions is not in a position to apply the label's own contraindications. The absence of the questions is itself an answer.
Can telehealth services prescribe compounded GLP-1s?
What a service prescribes varies: branded product, an authorized generic, or a compounded preparation are three different things, and a reader is entitled to know in plain words which one is being sent before paying or swallowing anything. The distinction changes what is in the box, how the dose is expressed and what questions belong to the pharmacy. The site has a page of questions to ask before filling at a compounding pharmacy, and one on tracking compounded semaglutide, which covers exactly those differences.
What happens to my health data if I stop a telehealth subscription?
That varies by service, which is exactly why it belongs on the list of questions asked before signing up rather than after cancelling. Health data entered into a service is held by that service, and the terms that govern retention, export and deletion are the service's own. Worth asking alongside: whether stopping means losing access to the prescriber, the medicine, or the records. The site's position on local-only tracking, where data stays on the phone, is explained separately.